DNAnexus Partners with SolveBio
News Apr 22, 2016
DNAnexus Inc. has announced a partnership with SolveBio to integrate the two platforms and provide seamless access to SolveBio’s curated data and analysis services. Researchers globally will have the ability to move quickly from genomic data analysis to interpretation, freeing up time to focus on generating uniquely actionable biological insights.
DNAnexus combines expertise in cloud computing and bioinformatics to provide the global network for organizations that are pursuing genomic-based approaches to health, in the clinic and in the research lab. DNAnexus provides pharmaceutical and biotech companies, global diagnostic test providers, genome centers, and sequencing service providers the infrastructure and scientific support to solve genomic challenges faster and more effectively than ever before.
“Both DNAnexus and SolveBio make genomic data more accessible, easier to analyze, and more actionable,” said Richard Daly, CEO of DNAnexus. “We view the integration of DNAnexus’ and SolveBio’s complementary product offerings as a way help to remove barriers to genomic insight and provide better solutions to enterprises globally.”
SolveBio gathers, secures, and monitors real-time, critical Genomics Intelligence for the pharmaceutical and global diagnostic markets. Access to the latest discoveries and expert assessments in genomics guides key investment decisions in R&D and treatment plans in the clinic.
SolveBio turns evaluating and using internal and external insights and information into a standardized task-oriented process for scientists, clinicians, and directors. Integrating with genomic analysis companies allows enterprises leveraging genomics to bring Genomics Intelligence into any workflow or pipeline in a standardized process.
“Our passion is to help scientists make sense of complexity and to use that intelligence to drive issues around human health,” said Mark Kaganovich, CEO of SolveBio. “Our goals are aligned with those of DNAnexus and an integration between our solutions makes a great deal of sense. We look forward to our collective customers being able to seamlessly integrate their analyses with the contextual information that SolveBio provides.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.